IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma

Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal...

Related Keywords

Canada ,Sydney ,New South Wales ,Australia ,Melbourne ,Victoria ,Grand Rapids ,Michigan ,United States ,Anthony Joshua ,Darrin Beaupre ,Sreenivasar Chandana ,Head Department Of Medical Oncology ,Biosciences Inc ,Alfred Health ,Kinghorn Cancer Centre ,Exchange Commission ,Cancer Hematology Centers In Grand Rapids ,Novartis ,Nasdaq ,Chief Medical Officer ,Medical Oncologist ,Hematology Centers ,Professor Anthony Joshua ,Head Department ,Medical Oncology ,Royal Victorian Eye ,Ear Hospital ,Orphan Drug ,Vice President ,Chief Financial Officer ,Ideaya Biosciences ,Nc ,